Get the Stockscreener App
0.505
0.98%
0.0049
After Hours:
.49
-0.015
-2.97%
Turnstone Biologics Corp stock is traded at $0.505, with a volume of 139.57K.
It is up +0.98% in the last 24 hours and down -1.41% over the past month.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.5001
Open:
$0.491
24h Volume:
139.57K
Relative Volume:
0.50
Market Cap:
$11.97M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-67.40M
1W Performance:
+9.81%
1M Performance:
-1.41%
6M Performance:
-80.58%
1Y Performance:
-80.50%
1-Day Range:
$0.4885
$0.545
1-Week Range:
$0.443
$0.545
52-Week Range:
$0.4393
$5.75
Turnstone Biologics Corp Stock (TSBX) Company Profile
Name
Turnstone Biologics Corp
Sector
Industry
Phone
347-897-5988
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Compare TSBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.505 | 11.97M | 81.89M | -55.20M | -67.40M | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-14-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-16-23 | Initiated | SVB Securities | Market Perform |
| Aug-15-23 | Initiated | BofA Securities | Buy |
| Aug-15-23 | Initiated | Piper Sandler | Overweight |
Turnstone Biologics Corp Stock (TSBX) Latest News
Turnstone Biologics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Turnstone Biologics stock downgraded amid concerns over therapy scalability and funding - Investing.com
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - The Manila Times
Turnstone Biologics Faces Financial and Operational Challenges - TipRanks
Turnstone Biologics Reports 25% Response Rate in Cancer Trial, Extends Cash Runway to 2026 | TSBX Stock News - StockTitan
Turnstone advances TIL therapy for solid tumors at SITC meeting By Investing.com - Investing.com Australia
Turnstone advances TIL therapy for solid tumors at SITC meeting - Investing.com
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
Turnstone Biologics Reveals Breakthrough TIL Cancer Treatment Data at SITC 2024 | TSBX Stock News - StockTitan
Warning: TSBX is at high risk of performing badly - MSN
Turnstone Biologics (NASDAQ:TSBX) & Recursion Pharmaceuticals (NASDAQ:RXRX) Critical Contrast - Defense World
BofA downgrades Turnstone stock, citing wait-and-see approach until 2025 data - Investing.com
Turnstone fires most staff in bid to to extend runway - The Pharma Letter
Turnstone Biologics Streamlines Operations and Leadership - Yahoo Finance
Turnstone Biologics announces strategic cuts and focus shift - Investing.com
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway - ForexTV.com
Turnstone Biologics stock plunges to 52-week low of $0.45 - Investing.com
Turnstone Biologics Corp. (NASDAQ:TSBX) Short Interest Update - Defense World
Turnstone Biologics stock hits 52-week low at $0.58 amid sharp decline - Investing.com
Analyzing Organovo (NASDAQ:ONVO) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Reviewing Krystal Biotech (NASDAQ:KRYS) & Turnstone Biologics (NASDAQ:TSBX) - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.67 - Investing.com
Turnstone Biologics stock plunges to 52-week low of $0.67 By Investing.com - Investing.com Canada
Taking on analysts’ expectations and winning: Turnstone Biologics Corp (TSBX) - SETE News
Investor’s Delight: Turnstone Biologics Corp (TSBX) Closes Strong at 0.70, Up 1.15 - The Dwinnex
Is Turnstone Biologics Corp (TSBX) a good investment opportunity? - US Post News
Turnstone Biologics Corp. (NASDAQ:TSBX) Sees Significant Increase in Short Interest - Defense World
Turnstone Biologics stock plunges to 52-week low of $0.72 - Investing.com
Turnstone Biologics price target lowered to $10 from $12 at BofA - TipRanks
Tourmaline Bio (NASDAQ:TRML) versus Turnstone Biologics (NASDAQ:TSBX) Head-To-Head Review - Defense World
The time has not yet come to remove your chips from the table: Turnstone Biologics Corp (TSBX) - SETE News
Turnstone Biologics Corp’s results are impressive - US Post News
Turnstone Biologics (NASDAQ:TSBX) Price Target Cut to $3.75 by Analysts at Piper Sandler - Defense World
Turnstone Biologics shares target cut by Piper Sandler with no rating change - Investing.com
TSBX’s Stock Market Adventure: -70.07% YTD Growth Amidst Volatility - The InvestChronicle
Market Momentum: Turnstone Biologics Corp (TSBX) Registers a -8.24 Decrease, Closing at 0.76 - The Dwinnex
Turnstone Biologics price target lowered to $3.75 from $20 at Piper Sandler - TipRanks
SVB Securities slashes price target on Turnstone Biologics Corp [TSBX] – find out why. - The DBT News
Turnstone Biologics (NASDAQ:TSBX) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS - Defense World
Take off with Turnstone Biologics Corp (TSBX): Get ready for trading - SETE News
Turnstone Biologics stock plunges to 52-week low of $1.36 By Investing.com - Investing.com Canada
Why Is Turnstone Biologics Stock Trading Lower On Thursday?Turnstone Biologics (NASDAQ:TSBX) - Benzinga
Turnstone Biologics stock plunges to 52-week low of $1.36 - Investing.com
Turnstone reports positive early trial results for cancer therapy - Investing.com
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today? - InvestorPlace
Turnstone Biologics Reports Encouraging Phase 1 Results - TipRanks
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights - ForexTV.com
Turnstone Biologics reports Q2 EPS (92c), consensus (93c) - TipRanks
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer - StockTitan
Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts - Insider Monkey
Turnstone Biologics Corp Stock (TSBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):